
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Rab GDI α CRISPR/Cas9 KO Plasmid (h) | sc-404659 | 20 µg | $397.00 |
GDI1 encodes Rab GDP dissociation inhibitor alpha (Rab GDI α), a cytosolic chaperone that binds prenylated Rab GTPases and regulates their extraction from membranes, solubilization, and recycling between donor and acceptor compartments. By controlling Rab availability and localization, Rab GDI α helps coordinate vesicle budding, trafficking, and fusion across endocytic and secretory pathways, supporting organelle identity and cargo sorting. Disruption of GDI1 perturbs Rab-dependent trafficking networks that are critical for synaptic vesicle cycling and neuronal homeostasis, linking altered membrane transport to neurodevelopmental and neurological disease phenotypes. As a central node in small GTPase regulation, GDI1 is frequently studied in the context of endosome dynamics, Golgi-to-plasma membrane transport, and synaptic function.
Rab GDI α CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the GDI1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the GDI1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the GDI1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Rab GDI α protein expression.
This CRISPR knockout system enables efficient generation of GDI1-deficient cell models for investigation of Rab GDI α signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
CRISPRs +/- HDRs
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.